Zanubrutinib
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206830

CAS#: 1558036-85-3

Description: Zanubrutinib, aslo known as BGB-3111, is a potent and highly selective small molecule BTK inhibitor which we are developing for the treatment of a variety of lymphomas. Upon administration, BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 850
Size
Price

25mg
USD 250
Size
Price

50mg
USD 450

Zanubrutinib is under synthesis, which may be available by the end of January 2018. We accept orders now. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 206830
Name: Zanubrutinib
CAS#: 1558036-85-3
Chemical Formula: C24H25N5O3
Exact Mass: 431.1957
Molecular Weight: 431.496
Elemental Analysis: C, 66.81; H, 5.84; N, 16.23; O, 11.12


Synonym: BGB-3111; BGB 3111; BGB3111; Zanubrutinib.

IUPAC/Chemical Name: (R)-1-(1-Acryloylpiperidin-3-yl)-5-amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide

InChi Key: WTLRSSATGYETCG-QGZVFWFLSA-N

InChi Code: InChI=1S/C24H25N5O3/c1-2-20(30)28-14-6-7-17(15-28)29-23(25)21(24(26)31)22(27-29)16-10-12-19(13-11-16)32-18-8-4-3-5-9-18/h2-5,8-13,17H,1,6-7,14-15,25H2,(H2,26,31)/t17-/m1/s1

SMILES Code: O=C(C1=C(N)N([C@H]2CN(C(C=C)=O)CCC2)N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)N


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

BTK, a member of the TEC family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.


References

1: Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation
BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.
Review. PubMed PMID: 26957112; PubMed Central PMCID: PMC4784459.

2: Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine
kinase. J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y.
Review. PubMed PMID: 27590878; PubMed Central PMCID: PMC5010774.

3: Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench
to bedside. Oncotarget. 2017 Jan 24;8(4):7201-7207. doi:
10.18632/oncotarget.12786. Review. PubMed PMID: 27776353; PubMed Central PMCID:
PMC5351700.